ERBB2 and breast carcinoma: In HER2+ breast cancer patients with BMs, the addition of tucatinib to trastuzumab and capecitabine doubled the objected-response rate, reduced the risk of intracranial progression or death by two-thirds, and reduced the risk of death by almost half [111].